Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SI-B001 + paclitaxel or carboplatin
- Development stage
- Unknown
- Lead developer
- SystImmune
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**SI-B001 + paclitaxel or carboplatin** is a combination therapy investigated for treating locally advanced or metastatic epithelial cancers, notably EGFR/ALK wild-type non-small cell lung cancer (NSCLC). SI-B001 (izalontamab) is a novel bispecific monoclonal antibody targeting both **Epidermal growth factor receptor (EGFR)** and **ErbB-3 receptor (HER3)**. It is designed as an IgG-(scFv)2 bispecific antibody, and has demonstrated antitumor activity both as monotherapy and in combination with chemotherapy agents such as paclitaxel (AP) or carboplatin (TP)[1][3][4]. The combination specifically aims to block EGFR and HER3 signaling pathways, overcoming resistance mechanisms and enhancing the efficacy of standard chemotherapy. Clinical trials show promising objective response rates and manageable toxicity profiles. The combination is currently being studied in phase II and phase III trials for NSCLC lacking actionable genomic alterations, with additional suitability for other epithelial carcinomas[1][2][4].
- Other names
- SI-B001 + AP or TP
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on SI-B001 + paclitaxel or carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SI-B001 + paclitaxel or carboplatin.